Return to homepagePandemic Pact

R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT

  • Funded by Biomedical Advanced Research and Development Authority (BARDA)
  • Total publications:0 publications

Grant number: 75A50123C00064

Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    2023
    2025

  • Known Financial Commitments (USD)

    $748,039

  • Funder

    Biomedical Advanced Research and Development Authority (BARDA)

  • Research Location

    United States of America

  • Lead Research Institution

    PARTNER THERAPEUTICS, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT